TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27130973

Group type: COMPARATOR
Intervention: 16 Gy radiation (Oraya, OT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional anti-VEGF therapy
Number of subjects: 0
Study: 24351072

Group type: EXPERIMENTAL
Intervention: 4 g of myo-inositol/die plus 400 mcg of folic acid/die orally for six months
Number of subjects: 50

Group type: COMPARATOR
Intervention: 1 g of D-chiro-inositol/die plus 400 mcg of folic acid/die orally for six months
Number of subjects: 50
Study: 22414875

Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 19523875

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (1000 mg/day for 12 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (no omega-3 supplementation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Active control (exercise training without omega-3)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Inactive control (no exercise training)
Number of subjects: 40
Study: 18569546

Group type: EXPERIMENTAL
Intervention: Loaded parallel squats followed by countermovement jumps
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Countermovement jumps followed by loaded parallel squats
Number of subjects: 8

Group type: COMPARATOR
Intervention: Countermovement jumps
Number of subjects: 8
Study: 15831642

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronisation Therapy (CRT)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 124
Study: 14568269

Group type: EXPERIMENTAL
Intervention: 9 mcg of consensus interferon plus ribavirin (1000/1200 mg/daily) for 24 weeks (group A)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: 18 mcg of consensus interferon plus ribavirin (1000/1200 mg/daily) for 24 weeks (group B)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: 9 mcg of consensus interferon plus ribavirin for 48 weeks (group C)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: 18 mcg of consensus interferon plus ribavirin for 48 weeks (group D)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Overall sustained response in patients with genotype 2/3
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Overall sustained response in patients with genotype 1
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: 9 mcg of consensus interferon plus ribavirin for 48 weeks in naive genotype 1 patients
Number of subjects: 193
Study: 10591300

Group type: EXPERIMENTAL
Intervention: Financial sanctions for failing to verify vaccinations (experimental group)
Number of subjects: 911

Group type: COMPARATOR
Intervention: No financial sanctions (control group)
Number of subjects: 911
Study: 8982555

Group type: EXPERIMENTAL
Intervention: 1α-hydroxycalciferol (1α[OH]D3) at a low dose (0.25 μg/day, n = 56, Group L)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: 1α-hydroxycalciferol (1α[OH]D3) at a higher dose (0.5 to 1.0 μg/day, average 0.58 ± 0.02 μg/day, n = 65, Group H)
Number of subjects: 165

Group type: COMPARATOR
Intervention: No treatment (n = 44, Group N)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: 1α-hydroxycalciferol (1α[OH]D3)
Number of subjects: 165
Study: 1680275

Group type: EXPERIMENTAL
Intervention: Dimethindene maleate (4 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6195238

Group type: EXPERIMENTAL
Intervention: Total Body Exhaust Suit (TBE-suit)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional Theatre Clothing (C-clothing)
Number of subjects: 64
Study: 31539378

Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Moderate Intensity Continuous Training (MICT)
Number of subjects: 36
Study: 30075553

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) plus carbamazepine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Carbamazepine only (Control)
Number of subjects: 54
Study: 26481591

Group type: EXPERIMENTAL
Intervention: Iodixanol (non-ionic IOCM)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Ioxaglate (ionic LOCM)
Number of subjects: 146
Study: 23802779

Group type: EXPERIMENTAL
Intervention: Dominant language prime
Number of subjects: 21
Study: 22664561

Group type: EXPERIMENTAL
Intervention: Virtual reality training curriculum for colonoscopy
Number of subjects: 50
Study: 20397856

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Traditional progressive resistance exercise (TPRE)
Number of subjects: 16
Study: 18043492

Group type: EXPERIMENTAL
Intervention: Dexamethasone in decreasing doses
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 102
Study: 15715190

Group type: EXPERIMENTAL
Intervention: Oral temazepam plus nebulised Lignocaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous alfentanyl
Number of subjects: 50
Study: 12082590

Group type: EXPERIMENTAL
Intervention: GPIIb/IIIa antagonist orbofiban
Number of subjects: 924
Study: 10233322

Group type: EXPERIMENTAL
Intervention: Borage oil (500 mg daily)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (bland lipid miglyol)
Number of subjects: 160
Study: 7595759

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX) 2 mg/m2/d, days 1, 2; Etoposide 200-300 mg/m2/d, days 1-3; G-CSF 5-10 micrograms/d subcutaneously, days 4-18, every 4 weeks
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX) and Etoposide with G-CSF
Number of subjects: 9
Study: 2185680

Group type: EXPERIMENTAL
Intervention: Saphenofemoral flush ligation and multiple lower leg avulsions with leg exsanguinated with a Rhys‐Davies cuff and ischaemia maintained with a pneumatic tourniquet
Number of subjects: 100

Group type: COMPARATOR
Intervention: Identical surgery with a 30 degree head down tilt only
Number of subjects: 100
Study: 7319134

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (0.4 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral dihydrocodeine (60 mg)
Number of subjects: 0
Study: 31655984

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard of care (SoC)
Number of subjects: 55
Study: 27488754

Group type: EXPERIMENTAL
Intervention: Enhanced heart failure education with a 6-month telephone follow-up program (EHFP)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 248
Study: 25872504

Group type: EXPERIMENTAL
Intervention: Usual care with radiographs at 1, 2, 6, and 12 weeks post-trauma
Number of subjects: 697

Group type: COMPARATOR
Intervention: Radiographs beyond the initial follow-up only when clinically indicated
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 697
Study: 24225081

Group type: EXPERIMENTAL
Intervention: Protein supplementation (20 grams twice a day)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Isocaloric placebo
Number of subjects: 250

Group type: COMPARATOR
Intervention: No supplementation
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: All groups (including protein supplementation, isocaloric placebo, and no supplementation)
Number of subjects: 250
Study: 21273606

Group type: EXPERIMENTAL
Intervention: Saracatinib (175 mg daily, orally or via gastrostomy tube)
Number of subjects: 9
Study: 19470385

Group type: EXPERIMENTAL
Intervention: 5 mg rapamycin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2.5 mg rapamycin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17943687

Group type: EXPERIMENTAL
Intervention: Neurocognitive enhancement therapy (NET) + Work therapy (WT)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Work therapy (WT) alone
Number of subjects: 145
Study: 15283871

Group type: EXPERIMENTAL
Intervention: Systematic screening
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Opportunistic screening
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Routine clinical practice (Control)
Number of subjects: 10000
Study: 11483228

Group type: EXPERIMENTAL
Intervention: Extend Bar (30 g total carbohydrate, including 5 g uncooked cornstarch, 3 g protein, 3 g fat)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo Bar (30 g total carbohydrate, 3 g protein, 3 g fat)
Number of subjects: 28
Study: 9489591

Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg orally) with food
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg orally) after food
Number of subjects: 12

Group type: COMPARATOR
Intervention: Troglitazone (400 mg orally) fasting
Number of subjects: 12
Study: 7826783

Group type: EXPERIMENTAL
Intervention: Humidified gas
Number of subjects: 41

Group type: COMPARATOR
Intervention: Non-humidified gas
Number of subjects: 41
Study: 3057688

Group type: EXPERIMENTAL
Intervention: Azathioprine (Aza) conversion from cyclosporine (CsA)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Continuous cyclosporine (CsA) therapy
Number of subjects: 66
Study: 31797160

Group type: EXPERIMENTAL
Intervention: Time pressure in new patient visits
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Time pressure in follow-up visits
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Workplaces with values alignment and emphasis on quality
Number of subjects: 168
Study: 29316885

Group type: EXPERIMENTAL
Intervention: Monthly cash transfer (unconditional)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Conditional cash transfer on school attendance
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Once-off payment conditional on a clinic visit
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cash transfers (CTs)
Number of subjects: 120
Study: 28843616

Group type: EXPERIMENTAL
Intervention: Pirfenidone (2.403 mg/daily) for one year
Number of subjects: 43
Study: 26849930

Group type: EXPERIMENTAL
Intervention: RetroButton
Number of subjects: 97

Group type: COMPARATOR
Intervention: Interference Screw
Number of subjects: 97
Study: 23278858

Group type: EXPERIMENTAL
Intervention: MRI-based severity index
Number of subjects: 173
Study: 21244862

Group type: EXPERIMENTAL
Intervention: School-based dietary-behavioral-physical activity intervention
Number of subjects: 376

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 376
Study: 18058036

Group type: EXPERIMENTAL
Intervention: Social Integration Survey (SIS)
Number of subjects: 129
Study: 17634167

Group type: EXPERIMENTAL
Intervention: Walnut-enriched meat (WM)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control meat (CM)
Number of subjects: 22
Study: 15477286

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 61)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (n = 55)
Number of subjects: 116
Study: 11529540

Group type: EXPERIMENTAL
Intervention: Low-dose erythromycin (2.5 mg kg(‐1) per dose 6 hourly)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 9764584

Group type: EXPERIMENTAL
Intervention: Heterozygous mutation in the ATM gene (insertion A at NT 898)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control subjects (no mutations detected)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Estimated percentage of AT heterozygous patients in radiosensitive cases
Number of subjects: 80

Group type: COMPARATOR
Intervention: Estimated percentage of AT heterozygous patients in control subjects
Number of subjects: 80
Study: 7639372

Group type: EXPERIMENTAL
Intervention: alfentanil (20 micrograms/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: methohexital (0.5 mg/kg)
Number of subjects: 30
Study: 3146231

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Balanced anesthesia with enflurane/alfentanil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoflurane with premedication (flunitrazepam and atropine, combined with 70% N2O/30% O2)
Number of subjects: 0
Study: 29793467

Group type: EXPERIMENTAL
Intervention: MINISTOP intervention
Number of subjects: 315

Group type: COMPARATOR
Intervention: Basic pamphlet on dietary and physical activity behaviors (control group)
Number of subjects: 315
Study: 26695077

Group type: EXPERIMENTAL
Intervention: Dialysis with a Vitamin E (VE)‐coated dialysis membrane for 12 months
Number of subjects: 260

Group type: COMPARATOR
Intervention: Non‐VE coated equivalent dialysis for 12 months
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Baseline C3 levels
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: SC5b‐9 levels
Number of subjects: 260
Study: 25500372

Group type: EXPERIMENTAL
Intervention: DASH diet with high sodium
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: DASH diet with intermediate sodium
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: DASH diet with low sodium
Number of subjects: 390

Group type: COMPARATOR
Intervention: Control diet with low sodium
Number of subjects: 390
Study: 22722359

Group type: EXPERIMENTAL
Intervention: Sign-out checklist with faculty member review and feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard sign-out instruction
Number of subjects: 0
Study: 20478739

Group type: EXPERIMENTAL
Intervention: Method-of-limits (MLI) for thermal cold perception thresholds (CT)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Method-of-limits (MLI) for thermal warm perception thresholds (WT)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Method-of-limits (MLI) for thermal cold pain thresholds (CPT)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Method-of-limits (MLI) for heat pain thresholds (HPT)
Number of subjects: 38
Study: 18775821

Group type: EXPERIMENTAL
Intervention: Comprehensive biomedical health test including cardiovascular risk score (CVRS) followed by written advice and health consultations
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control group answering questionnaires
Number of subjects: 2000
Study: 16353930

Group type: EXPERIMENTAL
Intervention: True model (males not equal females)
Number of subjects: 50

Group type: COMPARATOR
Intervention: False model (males = females)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both models
Number of subjects: 50
Study: 12389657

Group type: EXPERIMENTAL
Intervention: Closure of subcutaneous fat layer with a running 3‐0 plain suture
Number of subjects: 327
Study: 10429836

Group type: EXPERIMENTAL
Intervention: Zanamivir 4 mg intravenously in healthy participants and those with mild/moderate renal impairment
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Zanamivir 2 mg intravenously in participants with severe renal impairment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Healthy participants receiving 4 mg zanamivir intravenously
Number of subjects: 17
Study: 8538187

Group type: EXPERIMENTAL
Intervention: 4-HPR at a dose of 200 mg po for five years in breast cancer study
Number of subjects: 2972

Group type: EXPERIMENTAL
Intervention: 4-HPR at a dose of 200 mg po for one year in basal cell carcinoma study
Number of subjects: 2972

Group type: EXPERIMENTAL
Intervention: 4-HPR at a dose of 200 mg po for one year in oral leukoplakia study
Number of subjects: 2972

Group type: COMPARATOR
Intervention: Control group (no treatment) in breast cancer study
Number of subjects: 2972

Group type: COMPARATOR
Intervention: Control group (no treatment) in basal cell carcinoma study
Number of subjects: 2972

Group type: COMPARATOR
Intervention: Control group (no treatment) in oral leukoplakia study
Number of subjects: 2972
Study: 2147161

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (100 mg)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Combination of medroxyprogesterone acetate and tamoxifen (2 x 10 mg)
Number of subjects: 195
Study: 38678

Group type: EXPERIMENTAL
Intervention: Ketotifen syrup
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30907624

Group type: EXPERIMENTAL
Intervention: LA Sprouts intervention (n=160)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Control group (n=130)
Number of subjects: 290
Study: 28430384

Group type: EXPERIMENTAL
Intervention: Intranasal naloxone 8 mg/0.4 ml
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intranasal naloxone 16 mg/0.4 ml
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous naloxone 1 mg/ml
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sublingual naloxone 16 mg/ml
Number of subjects: 12
Study: 26589371

Group type: EXPERIMENTAL
Intervention: Essential phospholipid (EPL) 1800 mg/day for 24 weeks, followed by 900 mg for 48 weeks
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Essential phospholipid (EPL)
Number of subjects: 324
Study: 24020649

Group type: EXPERIMENTAL
Intervention: Adenosine (18-24 mg) and Isoproterenol (20-30 mcg/min) administered intravenously after PVAI.
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Adenosine and Isoproterenol administration with supplemental ablation for non-PV triggers inducing AF (group 1A).
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Adenosine and Isoproterenol administration with supplemental ablation for non-PV foci that did not induce AF (group 1B).
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Adenosine and Isoproterenol administration with no further ablation for non-PV foci that did not induce AF (group 1C).
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group undergoing PVAI without drug challenge (group 2).
Number of subjects: 192
Study: 21857276

Group type: EXPERIMENTAL
Intervention: Continuous sciatic nerve block and continuous lumbar plexus blocks (group R, n = 19)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Single sciatic nerve block followed by saline infusion and continuous lumbar plexus block (group C, n = 19)
Number of subjects: 38
Study: 19232032

Group type: EXPERIMENTAL
Intervention: S100 + M2000 (sitagliptin 50 mg b.i.d. + metformin 1000 mg b.i.d.)
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: S100 + M1000 (sitagliptin 50 mg b.i.d. + metformin 500 mg b.i.d.)
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: M2000 (metformin 1000 mg b.i.d.)
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: M1000 (metformin 500 mg b.i.d.)
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: S100 (sitagliptin 100 mg q.d.)
Number of subjects: 1091

Group type: COMPARATOR
Intervention: PBO/M2000 (placebo switched to metformin 1000 mg b.i.d. at week 24)
Number of subjects: 1091
Study: 17515742

Group type: EXPERIMENTAL
Intervention: Naprapathic manual therapy (Index Group)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Evidence-based care (Control Group)
Number of subjects: 409
Study: 15024662

Group type: EXPERIMENTAL
Intervention: Tests of exertion of external force (lifting weight, pushing, pulling)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Tests of rapid movements (jumping, sprinting, kicking)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Tests of supporting body weight (chin‐ups, squats)
Number of subjects: 77
Study: 11594926

Group type: EXPERIMENTAL
Intervention: 150 mg remacemide hydrochloride
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 300 mg remacemide hydrochloride
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 600 mg remacemide hydrochloride
Number of subjects: 39

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 39
Study: 9561428

Group type: EXPERIMENTAL
Intervention: Binge eating disorder treatment
Number of subjects: 88
Study: 8076486

Group type: EXPERIMENTAL
Intervention: Carcinoembryonic antigen (CEA) monitoring every 3 months for two years, then every 6 months for the next three years.
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Carcinoembryonic antigen (CEA) monitoring for predicting hepatic metastases.
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Carcinoembryonic antigen (CEA) monitoring for predicting recurrent disease other than the liver.
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Carcinoembryonic antigen (CEA) as an indicator of subsequent recurrent disease.
Number of subjects: 311
Study: 2644750

Group type: EXPERIMENTAL
Intervention: Indomethacin (25‐50 mg bolus plus infusion, 5‐7.5 mg h‐1)
Number of subjects: 54
Study: 143188

Group type: EXPERIMENTAL
Intervention: Lithium treatment for 6 weeks
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 6
Study: 30288964

Group type: EXPERIMENTAL
Intervention: Many barriers condition
Number of subjects: 86

Group type: COMPARATOR
Intervention: Few barriers condition
Number of subjects: 86
Study: 27696795

Group type: EXPERIMENTAL
Intervention: Self-Efficacy for Exercise (SEE)
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Positive Outcome Expectations for Exercise (POEE)
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Baseline SEE
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Baseline POEE
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Important increases in physical activity level
Number of subjects: 514
Study: 26101038

Group type: EXPERIMENTAL
Intervention: BEWARE intervention (body awareness training)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Treatment as usual (physical therapy)
Number of subjects: 36
Study: 24332353

Group type: EXPERIMENTAL
Intervention: Automated software calculated approach
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manual target calculation
Number of subjects: 60
Study: 23529989

Group type: EXPERIMENTAL
Intervention: Dunaliella bardawil capsules
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (starch powder capsules)
Number of subjects: 34
Study: 19632880

Group type: EXPERIMENTAL
Intervention: Low load cranio‐cervical flexion (C‐CF) training
Number of subjects: 46

Group type: COMPARATOR
Intervention: Neck flexor strengthening exercises
Number of subjects: 46
Study: 17719285

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent implantation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Zotarolimus-eluting stent implantation
Number of subjects: 300
Study: 14962422

Group type: EXPERIMENTAL
Intervention: 0.5% levofloxacin (Quixin)
Number of subjects: 93

Group type: COMPARATOR
Intervention: 0.3% ciprofloxacin (Ciloxan)
Number of subjects: 93